Table 3.
Association between AMACR (5p13) polymorphisms and clinical factors in prostate cancer patients.
| rs2278008 | AG + GG (%) | AA (%) | OR (95% CI) | P | Adjusted OR (95% CI)a | P | G (%) | A (%) | OR (95% CI) | P | Adjusted OR (95% CI)a | P | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gleason score | |||||||||||||
| <7 | 29 (59.2) | 70 (48.3) | Ref. | Ref. | 30 (58.8) | 168 (49.9) | Ref. | Ref. | |||||
| ≥7 | 20 (40.8) | 75 (51.7) | 0.64 (0.33–1.24) | 0.1883 | 0.63 (0.32–1.24) | 0.1845 | 21 (41.2) | 169 (50.1) | 0.70 (0.38–1.26) | 0.2340 | 0.69 (0.38–1.28) | 0.2418 | |
| pTstage | |||||||||||||
| ≤pT2b | 12 (24.5) | 34 (23.4) | Ref. | Ref. | 12 (23.5) | 80 (23.7) | Ref. | Ref. | |||||
| ≥pT2c | 37 (75.5) | 111 (76.6) | 0.94 (0.44–2.01) | 0.8822 | 1.00 (0.47–2.15) | 0.9904 | 39 (76.5) | 257 (76.3) | 1.01 (0.51–2.02) | 0.9739 | 1.07 (0.53–2.15) | 0.8487 | |
|
| |||||||||||||
| rs34677 | GT + TT (%) | GG (%) | T (%) | G (%) | |||||||||
|
| |||||||||||||
| Gleason score | |||||||||||||
| <7 | 26 (51.0) | 73 (51.0) | Ref. | Ref. | 30 (53.6) | 168 (50.6) | Ref. | Ref. | |||||
| ≥7 | 25 (49.0) | 70 (49.0) | 1.00 (0.53–1.90) | 0.9933 | 1.06 (0.55–2.05) | 0.8558 | 26 (46.4) | 164 (49.4) | 0.89 (0.50–1.57) | 0.6811 | 0.93 (0.52–1.66) | 0.7990 | |
| pTstage | |||||||||||||
| ≤pT2b | 18 (35.3) | 28 (19.6) | Ref. | Ref. | 20 (35.7) | 72 (21.7) | Ref. | Ref. | |||||
| ≥pT2c | 33 (64.7) | 115 (80.4) | 0.45 (0.22–0.91) | 0.0254 | 0.42 (0.21–0.87) | 0.0193 | 36 (64.3) | 260 (78.3) | 0.50 (0.27–0.91) | 0.0243 | 0.48 (0.26–0.89) | 0.0191 | |
|
| |||||||||||||
| rs2287939 | CT + TT (%) | CC (%) | T (%) | C (%) | |||||||||
|
| |||||||||||||
| Gleason score | |||||||||||||
| <7 | 27 (60.0) | 72 (48.3) | Ref. | Ref. | 31 (60.8) | 167 (49.6) | Ref. | Ref. | |||||
| ≥7 | 18 (40.0) | 77 (51.7) | 0.62 (0.32–1.23) | 0.1716 | 0.52 (0.25–1.05) | 0.0686 | 20 (39.2) | 170 (50.4) | 0.63 (0.35–1.16) | 0.1372 | 0.54 (0.29–1.01) | 0.0536 | |
| pTstage | |||||||||||||
| ≤pT2b | 12 (26.7) | 34 (22.8) | Ref. | Ref. | 14 (27.5) | 78 (23.1) | Ref. | Ref. | |||||
| ≥pT2c | 33 (73.3) | 115 (77.2) | 0.81 (0.38–1.74) | 0.5952 | 0.84 (0.38–1.81) | 0.6492 | 37 (72.5) | 259 (76.9) | 0.80 (0.41–1.55) | 0.5011 | 0.83 (0.42–1.64) | 0.5966 | |
|
| |||||||||||||
| rs10941112 | GA + AA (%) | GG (%) | A (%) | G (%) | |||||||||
|
| |||||||||||||
| Gleason score | |||||||||||||
| <7 | 54 (43.2) | 45 (65.2) | Ref. | Ref. | 70 (45.5) | 128 (54.7) | Ref. | Ref. | |||||
| ≥7 | 71 (56.8) | 24 (34.8) | 2.47 (1.34–4.53) | 0.0037 | 2.28 (1.22–4.29) | 0.0101 | 84 (54.5) | 106 (45.3) | 1.45 (0.96–2.18) | 0.0751 | 1.39 (0.91–2.11) | 0.1272 | |
| pTstage | |||||||||||||
| ≤pT2b | 22 (17.6) | 24 (34.8) | Ref. | Ref. | 28 (18.2) | 64 (27.4) | Ref. | Ref. | |||||
| ≥pT2c | 103 (82.4) | 45 (65.2) | 2.50 (1.27–4.91) | 0.0080 | 2.60 (1.30–5.21) | 0.0071 | 126 (81.8) | 170 (72.6) | 1.69 (1.03–2.79) | 0.0389 | 1.77 (1.07–2.95) | 0.0272 | |
|
| |||||||||||||
| rs3195676 | GA + AA (%) | GG (%) | A (%) | G (%) | |||||||||
|
| |||||||||||||
| Gleason score | |||||||||||||
| <7 | 54 (43.9) | 45 (65.2) | Ref. | Ref. | 70 (46.1) | 128 (55.2) | Ref. | Ref. | |||||
| ≥7 | 69 (56.1) | 24 (34.8) | 2.40 (1.30–4.41) | 0.0050 | 2.35 (1.26–4.41) | 0.0076 | 82 (53.9) | 104 (44.8) | 1.44 (0.96–2.17) | 0.0808 | 1.39 (0.92–2.12) | 0.1203 | |
| pTstage | |||||||||||||
| ≤pT2b | 22 (17.9) | 24 (34.8) | Ref. | Ref. | 28 (18.4) | 64 (27.6) | Ref. | Ref. | |||||
| ≥pT2c | 101 (82.1) | 45 (65.2) | 2.45 (1.24–4.82) | 0.0095 | 2.66 (1.33–5.34) | 0.0057 | 124 (81.6) | 168 (72.4) | 1.69 (1.02–2.78) | 0.0408 | 1.78 (1.07–2.95) | 0.0259 | |
pTstage: pathologic stage; OR: odds ratio; 95% CI: 95% confidence interval; AMACR: (R)-alpha-methyl-CoA racemase.
aAdjusted for age, smoking quantity, alcohol drinking, and family history of prostate cancer.